Bli medlem
Bli medlem

Du är här



GHENT, Belgium, 26 March 2015
-Ablynx[Euronext Brussels: ABLX; OTC: ABYLY]

today announced an extension of its initial two-year research collaboration
with Merck&Co., Inc., known as MSD outside the United States and Canada, to
develop and commercialise Nanobody® candidates directed towards an
undisclosed voltage gated ion channel.

Merck&Co., Inc. will extend their funding of the research collaboration with
Ablynx to the end of September 2016. This ion channel collaboration was
announced in October 2012 and included a €6.5 million upfront payment and €2
million in initial research funding.

Merck and Ablynx have a separate collaboration in the field of cancer
immuno-therapy, announced in February in 2014, with a €20 million upfront
payment, €10.7 million in research funding and total potential milestone
payments of up to €1.7 billion plus royalties.

Commenting on the announcement, Dr Edwin Moses, CEO of Ablynx, said

"We are pleased to extend the research funding for our current ion channel
collaboration with Merck. To date, we have made encouraging progress in the
discovery of Nanobodies against this very challenging target and the
extension will potentially allow us to build on these advances."

As part of its hybrid model of developing its wholly-owned assets and
partnering some programmes, Ablynx has research and development
collaborations with multiple pharmaceutical companies including AbbVie,
Boehringer Ingelheim, Eddingpharm, Merck&Co., Inc., Merck Serono and Novartis
involving more than 20 active therapeutic programmes and which have already
generated more than €340 million in non-dilutive cash for the Company.

About the ion channel collaboration between Ablynx and Merck&Co., Inc.

In October 2012, Ablynx and a subsidiary of Merck&Co entered into a
collaboration to develop and commercialise Nanobody candidates directed
towards a voltage gated ion channel, with the option to develop and
commercialise a Nanobody to a second target. Under the terms of the
agreement, Merck gains exclusive global rights to Nanobodies against the
selected target, with an option for similar rights to a second target. Upon
signing, Merck paid Ablynx a €6.5 million upfront payment. In addition,
Ablynx is eligible to receive research funding and up to €448 million in
research, regulatory and commercial milestone payments associated with the
progress of multiple candidates, as well as tiered royalties on any products
derived from the collaboration. Ablynx is responsible for the discovery of
Nanobody candidates and Merck is responsible for the research, development,
manufacturing and commercialisation of any Nanobody product resulting from
the collaboration.

About Ablynx

Ablynxis a biopharmaceutical company engaged in the development ofNanobodies®,
proprietary therapeutic proteins based on single-domain antibody fragments,
which combine the advantages of conventional antibody drugs with some of the
features of small-molecule drugs. Ablynx is dedicated to creating new
medicines which will make a real difference to society. Today, the Company
has more than30 proprietary and partnered programmesin development in various
therapeutic areas including inflammation, haematology, oncology and
respiratory disease. The Company has collaborations with multiple
pharmaceutical companies including AbbVie, Boehringer Ingelheim, Eddingpharm,
Merck&Co. Inc., Merck Serono and Novartis. The Company is headquartered in
Ghent, Belgium. More information can be found

For more information, please contact


Dr Edwin Moses
t: +32 (0)9 262 00 07
m: +32 (0)473 39 50 68

Marieke Vermeersch
Associate Director Investor Relations
t: +32 (0)9 262 00 82
m: +32 (0)479 49 06 03

Follow us on Twitter @AblynxABLX

Ablynx media relations
Consilium Strategic Communications:

Mary-Jane Elliott, Jonathan Birt, Amber Bielecka, Lindsey Neville
t: +44 203 709 5700

pdf format of the press release


This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Ablynx via Globenewswire


Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.